Xenon Pharmaceuticals Inc. (XENE)’s Financial Results Comparing With Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO)

Since Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenon Pharmaceuticals Inc. N/A 12273.10 31.50M -1.64 0.00
Aerpio Pharmaceuticals Inc. 20.16M 6.91 8.11M -0.44 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Xenon Pharmaceuticals Inc. and Aerpio Pharmaceuticals Inc.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Xenon Pharmaceuticals Inc. 0.00% -64.5% -39.3%
Aerpio Pharmaceuticals Inc. -40.23% -22.7% -18.5%

Liquidity

Xenon Pharmaceuticals Inc.’s Current Ratio is 29.3 while its Quick Ratio is 29.3. On the competitive side is, Aerpio Pharmaceuticals Inc. which has a 19.2 Current Ratio and a 19.2 Quick Ratio. Xenon Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Aerpio Pharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors held 70.4% of Xenon Pharmaceuticals Inc. shares and 28% of Aerpio Pharmaceuticals Inc. shares. Insiders held 0.6% of Xenon Pharmaceuticals Inc. shares. Comparatively, Aerpio Pharmaceuticals Inc. has 0.8% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xenon Pharmaceuticals Inc. -16.96% -28.93% -52.38% 1.45% 197.87% 147.79%
Aerpio Pharmaceuticals Inc. 11.58% 0.95% -42.86% -44.21% -64.37% -55.37%

For the past year Xenon Pharmaceuticals Inc. had bullish trend while Aerpio Pharmaceuticals Inc. had bearish trend.

Summary

Aerpio Pharmaceuticals Inc. beats Xenon Pharmaceuticals Inc. on 5 of the 9 factors.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its preclinical product candidate includes XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of childhood epilepsy disorders. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd.; Genentech, Inc.; uniQure Biopharma B.V.; and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.